ArticleOpen heart2025
Assessment of β-blocker use and all-cause mortality in patients with myocardial infarction: a real-world analysis of the NHANES 1999-2018 database.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association between β-blocker use and all-cause mortality in a real-world cohort of patients with myocardial infarction (MI).
methodsThis study included 2308 patients with MI from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. The primary outcome was all-cause mortality. Multiple approaches were employed to control for confounding, including multivariable Cox regression, propensity score matching and inverse probability of treatment weighting.
resultsBased on data from 2308 patients with MI in the NHANES 1999-2018, with a mean follow-up of 84.6 months, this study evaluated the association between β-blocker use and all-cause mortality. The unadjusted analysis showed a significant protective effect (HR 0.81, 95% CI 0.68 to 0.96, p=0.0178). However, after multivariable adjustment for demographic, clinical and socioeconomic factors, as well as propensity score-based methods and inverse probability of treatment weighting, no significant association was observed (e.g., adjusted HR 1.04, 95% CI 0.87 to 1.25, p=0.6733). Stratified analyses did not reveal significant effect modification by any covariate (all p interaction value >0.05).
conclusionAfter adjustment for measured confounders, this analysis found no significant association between β-blocker use and all-cause mortality in this real-world MI cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.